Notably, the altered glucose sensing in pancreatic beta-cells, combined with lower insulin levels and higher blood glucose in CB2−/− mice, should be taken into consideration in view of the development of pharmacological cannabinoid receptor antagonists in diabetes therapy. This evidence concerns the gene INS and diabetes mellitus.